Introduction
The melatonin concentrating hormone receptor type 1 (MCHR1) is a G protein coupled receptor (GPCR) that is expressed both in the mammalian brain and in the periphery (Chung et al., 2009) . Within the CNS, receptor expression is most abundant in the cortex, hippocampus, amygdala, and nucleus accumbens (Saito et al., 2001; Chung et al., 2010) . Stimulation with melanocortin concentrating hormone (MCH), the receptor's endogenous ligand, triggers Gα i mediated inhibition of cAMP formation and consequent downstream signaling (Saito et al., 1999; Shimomura et al., 1999) . In contrast to the wide tissue distribution of the receptor, expression of MCH in the brain is restricted to the hypothalamus and zona incerta (Pissios and Maratos-Flier, 2003; Antal-Zimanyi and Khawaja, 2009 ).
Extensive genetic and pharmacological studies in rodents have implicated the MCH system in the control of feeding and metabolism, as well as in anxiety and depression.
Central injection or infusion of MCH (Qu et al., 1996; Gomori et al., 2003) , or overexpression of the corresponding gene (Ludwig et al., 2001) leads to increased food intake, whereas genetic deletion of MCH expression results in lean mice (Shimada et al., 1998; Kokkotou et al., 2005; Alon and Friedman, 2006) . Consistent with these observations, animals with targeted disruption of the MCHR1 gene have reduced body weight (Chen et al., 2002; Marsh et al., 2002) . The role of this receptor in modulating body weight is also supported by pharmacological studies using drugs that block MCHR1 function. Acute administration of a small molecule antagonist, SNAP-7941, to rodents was shown to decrease MCH-induced food intake. When the same drug was chronically This article has not been copyedited and formatted. The final version may differ from this version. given to rats with diet induced obesity, a decrease in body weight resulted (Borowsky et al., 2002) . Since these initial observations, an increasing number of small molecule MCHR1 antagonists have been studied in rodents and shown to reduce body weight. In addition, several of these antagonists including SNAP-7941 show anxiolytic and/or antidepressant properties when assessed in murine models (Antal-Zimanyi and Khawaja, 2009; Chung et al., 2010) . The development of MCHR1 antagonists is therefore being actively pursued as a potential therapeutic for obesity and/or mood disorders in humans.
To explore whether naturally occurring genetic alterations in the MCHR1 predispose to obesity, there has been ongoing interest in identifying human variants of this receptor.
Two of these naturally occurring mutants, D32N and R317Q, have been pharmacologically characterized in vitro. With both of these variants, function and expression were indistinguishable from corresponding wild type values (Gibson et al., 2004; Wermter et al., 2005) .
To determine the potential impact of eleven additional MCHR1 missense variants that have been reported in the literature and in genomic databases (Gasteiger et al., 2003; Wermter et al., 2005; Wheeler et al., 2008) , we pharmacologically characterized each of these receptor isoforms. When compared with wild type, we found that several mutations cause a significant alteration in MCH efficacy with little if any impact on agonist potency or receptor expression. In addition, we discovered that two MCHR1 variants (R210H and S377P) virtually abolish receptor-mediated signaling. Consistent with the anticipated metabolic phenotype resulting from loss of function isoforms (i.e. reduced body weight), This article has not been copyedited and formatted. The final version may differ from this version. it is intriguing that the two inactivating MCHR1 mutations were identified in underweight subjects but not in a parallel cohort of obese individuals (Wermter et al., 2005) . This observation raises the possibility that selected MCHR1 variants protect against obesity. Our findings also suggest that certain effects of SNAP-7941 extend well beyond antagonist activity. This small molecule increases cell surface expression of the wild type receptor as well as rescues MCH responsiveness of one of the functionally deficient receptor mutants (P377S). The potential of MCHR1 antagonists to paradoxically enhance agonist stimulation, and the possible impact of pharmacogenomic variability, will need to be considered in the development of such compounds as therapeutics.
This article has not been copyedited and formatted. The final version may differ from this version. , and β -galactosidase have been described previously (Hearn et al., 2002; Beinborn et al., 2005; Beinborn et al., 2010) . MCH was purchased from Bachem (Torrance, CA).
,4-tetrahydropyrimidine-5-carboxylate] has previously been reported (Goss and Schaus, 2008) .
Cell Culture. Human embryonic kidney (HEK) 293 cells were grown in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), penicillin (100 U/ml), and streptomycin (100 μg/ml). The cells were maintained at 37°C in a humidified environment containing 5% CO 2 .
Receptor Plasmids. The MCHR1 encoding cDNA used in this study was obtained from cDNA was amplified by PCR and subcloned into pcDNA1.1 (Invitrogen), providing the wild type template for site-directed mutagenesis. Receptor constructs including missense polymorphisms/mutations (listed below) were generated by oligonucleotide-directed, site-specific mutagenesis as described previously (Blaker et al., 1998) . A parallel set of corresponding wild type and mutant constructs was also made in which a hemagglutinin epitope tag (YPYDVPDYA) was inserted between the first and second receptor amino acids (methionine and serine, respectively) thus enabling detection by ELISA. The coding region of each construct was sequenced to confirm introduction of only the designated amino acid substitutions.
Eight of the mutants that were pharmacologically characterized (shown in Fig. 1) correspond to SNPs listed in the ExPASy Proteomics server (www.expasy.ch) (Gasteiger et al., 2003) : T25M (Swiss Prot ID VAR_026652), D28V (VAR_026653), G34R
(VAR_026654), R210H (VAR_026655), Y250H (VAR_026656), T305M
(VAR_026657), P377S (VAR_026659), and T411M (VAR_026660). Three other mutants that were studied were found in the NCBI SNP database (http://www.ncbi.nlm.nih.gov/projects/SNP) (Wheeler et al., 2008) : Y107M (refSNP ID rs45623433), G401R (rs34214100), and G103R (rs11914085, also documented as Swiss Prot ID VAR_049417). An additional control construct was included to confirm the previously described phenotype of a D32N substitution (Wermter et al., 2005) .
Luciferase Reporter Gene Assays. Receptor-mediated signaling via inhibitory Gαi/o proteins was assessed using a luciferase reporter gene assay as described previously (Hearn et al., 2002; Al-Fulaij et al., 2008 transfection, the cells were incubated for 4-6 hours in medium containing MCH together with 5 x 10 -7 M forskolin, a receptor-independent stimulus of cAMP formation and consequent CRE6X-luciferase activity. The ability of MCH to trigger receptor-mediated inhibition of forskolin-induced luciferase activity was monitored as described above.
Additional control experiments compared ligand efficacy with transfection of 20 ng/well of receptor cDNA, and/or an interval of 24 hours between cell transfection and functional assessment. Using these modified conditions, MCH efficacies at the mutant vs. wild type receptors were similar to those observed with the standard protocol (4 ng receptor cDNA / 48 hours incubation).
In experiments to assess the effect of overnight exposure to SNAP-7941, 10 -6 M of this compound was added 24 hours after transfection. The following day, cells were washed five times with serum-free media, incubated for 4-6 hours with MCH (3 x 10 -6 M) and then lysed for assessment of luciferase activity.
ELISA of MCHR1 Expression. Receptor expression levels were determined using a procedure described by Al-Fulaij et al. (Al-Fulaij et al., 2008) . 
Results
We studied the effect of 11 naturally occurring missense mutations in the MCHR1 which have been reported in the literature and/or in selected databases (see Methods), but have not yet been pharmacologically characterized. In addition, the D32N polymorphism which was previously described as functionally normal was included as a control (Wermter et al., 2005) . A cartoon illustrating the location of individual amino changes within the receptor molecule is shown in Fig. 1 .
Following expression of MCHR1s in HEK293 cells, basal and agonist-induced signaling of each mutant was assessed relative to wild type (summarized in Table 1 ).
In the absence of MCH, all of the receptors lacked basal activity (i.e. signaling did not differ from vector-transfected control cells ("no receptor" in Table 1 ). Five variants, T25M, D28V, D32N, G34R, Y250H, showed MCH induced maximal activity comparable to that at the wild type receptor. In contrast, the maximal level of MCHstimulated function was significantly increased (by ~30-40%) in cells expressing the G401R or T401M receptor variants. Conversely, activity of MCH was reduced (by ~50% compared to wild type) with expression of either the G103R, Y107H, or T305M
isoforms. The most pronounced defects were observed with expression of the R210H and P377S variants. Each of these isoforms showed minimal if any activation when stimulated with MCH ( Fig. 2 top panel, Table 1 ).
This article has not been copyedited and formatted. The final version may differ from this version. whereas background in vector-transfected cells (no receptors) was defined as 0%. This analysis revealed that with one exception, both total and surface expression of all receptor variants was comparable with wild type (Table 1 ). The only significant difference was found with the G103R mutant where surface expression was 73% of the control value.
To confirm the major loss of function observed with the R210H and P377S mutations, signaling was examined using a second reporter gene assay (shown in Fig 2, (Table 2 ). Given some rare precedents for mutation induced conversion of antagonists to agonists (Strader et al., 1989; Blaker et al., 1998; Kopin et al., 2003) we also examined SNAP-7941 activity on the R210H and P377S variants.
Respective experiments revealed that this compound did not induce signaling at either of the mutants (not shown).
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The R210H substitution is localized within the "DRY" motif of the MCHR1. This amino acid sequence was shown in other GPCRs to play an essential role in determining the equilibrium between inactive and active receptor conformations (Rovati et al., 2007) .
Consistent with this function, a recent study showed that substitution of the corresponding arginine in the rat MCHR1 isoform with an alanine (R141A), resulted in a significant loss in MCH potency (Aizaki et al., 2009 ). It appears that the naturally occurring R210H substitution in the human MCHR1, as described here, has an even more pronounced impact by essentially abolishing MCH-induced stimulation.
The P377S substitution, which also leads to a loss of MCH-induced function, is located within a different highly conserved GPCR signature motif, NPXXY (where positions "X" can be occupied by any amino acids). Again, there is precedent with several receptors that modification of this important motif can compromise ligand induced activity and/or receptor expression (Wess et al., 1993; Gales et al., 2000; Mazna et al., 2008) .
Additional characterization of the MCHR1 variants which are unresponsive to MCH revealed that under basal conditions, cell surface expression is comparable to wild type. At the P377S mutant, not only does SNAP-7941 enhance surface expression but this compound also rescues the receptor's ability to signal (reflected by the fact that MCH activity at this variant is contingent on pre-incubation with the small molecule). In contrast, at the R210H mutant, SNAP-7941 treatment has no appreciable effect on either receptor expression or function.
The ability of SNAP-7941 to restore agonist induced signaling of the P377S mutant may reflect an ability of this ligand to stabilize the receptor in one or more conformations that are a prerequisite for agonist activity. It is now increasingly appreciated that GPCRs, like many other proteins, spontaneously undergo conformational changes with varying levels of structural stability (Kobilka and Deupi, 2007) . Biophysical studies revealed that Based on rodent studies, it is anticipated that either loss or gain of MCHR1 function will predispose to selected phenotypes in humans (e.g. a lean or obese phenotype respectively) (Antal-Zimanyi and Khawaja, 2009; Pissios, 2009; Chung et al., 2010) . As a candidate obesity susceptibility gene, the MCHR1 locus has therefore been screened for mutations (Gibson et al., 2004; Wermter et al., 2005) . The variants that have been identified to date are not associated with standard indices of obesity (including body mass index, waist circumference, and glucose tolerance) (Antal-Zimanyi and Khawaja, 2009).
However, it is of note that the two major loss-of-function variants described in our work (H210R and P377S) were respectively identified in two markedly underweight students, but not in an obese cohort that was studied in parallel (Wermter et al., 2005) . Although Luciferase activity was then measured and normalized using the corresponding β -galactosidase values. Results in each experiment were expressed relative to the forskolinstimulated control observed at each receptor in the absence of MCH (= 100%).
Data shown in both panels represent the mean ± SEM from at least four independent experiments, each performed in triplicate. This article has not been copyedited and formatted. The final version may differ from this version.
